Envafolimab Combined With Endostar in the First-line Treatment of Advanced NSCLC
Status:
Not yet recruiting
Trial end date:
2024-01-23
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of envafolimab combined with endostar in the first-line
treatment of advanced Non-small Cell Lung Cancer With PD-L1 positive expression